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Abstract The human ABIN-2 was originally identi¢ed as an
A20-associating cytosolic protein to block NF-UB activation
induced by various stimuli. Here we report that ABIN-2 has
the potential to enter the nucleus and plays a role in mediating
transcriptional activation in both yeast and mammalian cells.
The Gal4BD^ABIN-2 fusion protein is able to drive the expres-
sion of the GAL4-responsive reporter gene in yeast e⁄ciently
without the need of the Gal4p activation domain, suggesting
that ABIN-2 functions as a transcriptional coactivator and fa-
cilitates transcription in yeast. In contrast to the activity in
yeast, however, only the C-terminal fragment of ABIN-2 exerts
the transactivating activity in mammalian cells but not the full-
length ABIN-2 protein. This observation has led to the identi-
¢cation of the N-terminal 195 amino acids of ABIN-2 as a
regulatory domain, which retains the full-length ABIN-2 in
the cytoplasm of mammalian cells and thus cannot transacti-
vate. We have also found that BAF60a, a component of chro-
matin-remodeling complex, interacts with ABIN-2 by the yeast
two-hybrid analysis. Together, our results suggest that the nu-
clear ABIN-2 de¢nes a novel transcriptional coactivator and
acts presumably by recruiting a chromatin-remodeling complex
to the site of the target gene.
0 2003 Federation of European Biochemical Societies. Pub-
lished by Elsevier Science B.V. All rights reserved.
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1. Introduction
Elucidating the e¡ects of an inhibitor, called A20, has pro-
vided a key aspect to unravel the regulation of NF-UB activity
in the last decade [1]. A20 is a cytosolic zinc ¢nger protein and
was ¢rst identi¢ed as a tumor necrosis factor (TNF) respon-
sive gene in human endothelial cells [2^4]. It was subsequently
found that A20 inhibits NF-UB activity and TNF-mediated
programmed cell death [5^7]. The A20-dependent inhibition
of NF-UB requires a number of A20-associating proteins
called ABINs (A20-binding inhibitor of NF-UB activation).
Among these proteins are ABIN-1 and ABIN-2, which have
been characterized previously [1,8]. ABIN-1 is the murine ho-
molog of human immunode¢ciency virus Nef-associated fac-
tor, which has a canonical leucine zipper structure [8,9].
ABIN-2 is a novel cytosolic protein that shows no homology
with any other known protein [10]. Overexpression of ABIN-1
and ABIN-2 was su⁄cient to inhibit NF-UB activation in-
duced by TNF or interleukin-1 (IL-1). The step where ABINs
inhibited NF-UB activation was predicted to be upstream of
the IKK complex, since ABINs failed to inhibit NF-UB acti-
vation induced by overexpression of IKK directly [8,10].
LKB1 has been proposed as a tumor suppressor and the
causative gene of Peutz^Jeghers syndrome [11^13]. To inves-
tigate the cellular function of LKB1, we have previously
cloned ABIN-2, also known as FLIP1, as one of the LKB1-
interacting proteins by yeast two-hybrid screening [14]. In an
e¡ort to further explore the function of ABIN-2/FLIP1, we
have unexpectedly discovered that ABIN-2 has the potential
to enter the nucleus and possesses transactivating activity.
Thus, ABIN-2 may de¢ne a dual-functional protein that reg-
ulates NF-UB activation in the cytoplasm and behaves as a
novel transcriptional coactivator in the nucleus.
2. Materials and methods
2.1. Yeast two-hybrid analysis
The yeast two-hybrid system, including pPC62 (containing Gal4BD
(Gal4 binding domain)) and pPC86 (containing Gal4AD (Gal4 acti-
vation domain)) plasmids, used in this study has been described pre-
viously [15]. The yeast strain, PCY2 (MATKvgal4vgal80 URA3 : :
GAL1^LacZ lys2 his3 trp1 leu2 ade2), was routinely used in the
two-hybrid analysis and transactivation assay except the screening
of ABIN-2-interacting proteins. To screen for the ABIN-2-interacting
proteins, the host strain PCY2* was obtained by mutagenesis of
PCY2 with ethyl methanesulfonate (EMS; Sigma, St. Louis, MO,
USA) according to the published protocol [16]. The human cDNA
synthesized from hepatoma cell line, Huh7, was constructed into
pPC86 and used as prey in the two-hybrid screening. Yeast trans-
formation was performed by the lithium acetate procedure [16]. The
L-galactosidase activity was analyzed by the colony-lift ¢lter method
[17]and the appearance of blue color on the colonies within 2 h after
the addition of substrate was considered a positive reaction in this
assay. The positive reaction by the colony-lift ¢lter method was rou-
tinely recon¢rmed by the liquid assay [16].
2.2. Plasmid constructions and recombinant DNA technique
The full-length ABIN-2 DNA was cloned as described in a previous
study [14]. Various truncated ABIN-2 DNA fragments were generated
by polymerase chain reaction (PCR) ampli¢cation from the full-length
ABIN-2 DNA using speci¢c primers designed to match the sequence
at the truncation sites. A SalI-recognition sequence and a NotI-rec-
ognition sequence were always incorporated into the 3P and the 5P
primers, respectively, to allow a convenient cloning procedure follow-
ing the PCR reaction. The PCR products were digested with SalI and
NotI, and then ligated into pPC62 to form Gal4BD-fused ABIN-2
constructs. The mammalian expression constructs of the Gal4BD-
fused ABIN-2 equivalent to the yeast expression clones were carried
out by HindIII and NotI digestion of each pPC62^ABIN-2 and then
religated into the pcDNA3.0 vector (Invitrogen, CA, USA). For two
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truncated forms of BAF60a, BAF60a1380 was cut out by SalI and
XbaI digestion and BAF60a1304 was cut out by SalI and PstI diges-
tion from pPC62^BAF60a and religated into pPC62. The
BAF60a176476 fragment, on the other hand, was obtained by PCR
as described above.
2.3. Cell culture, transfection and luciferase assay
Human embryonic kidney cells, HEK 293T, were maintained in
Dulbecco’s modi¢ed Eagle’s medium (DMEM; Life Technologies,
MD, USA) supplemented with 10% fetal calf serum, 2 mM L-gluta-
mine, 3.7 mg/ml sodium bicarbonate, 100 unit/ml penicillin, 100 Wg/ml
streptomycin, and 100 WM non-essential amino acids. Transfection of
293T cells was performed using the standard calcium phosphate pre-
cipitation method [18].
For mammalian transactivation assay, 293T cells were ¢rst seeding
at 2.5U105 cells/well in a 12-well plate. The Gal4BD-fused ABIN-2
constructs were then cotransfected with GAL4-responsive luciferase
reporter plasmid (pFR-Luc; Stratagene, La Jolla, CA, USA). 22 h
after transfection, cells were lysed in lysis bu¡er (100 mM potassium
phosphate, pH 7.4, 1% Triton X-100, 1 mM dithiothreitol, and 20
mM EDTA). Cell debris was removed by centrifugation and 10 Wl of
cell extract was then used to measure the luciferase activity using the
Luciferase Assay kit (Promega, Madison, WI, USA) and an automatic
microplate luminometer. The luciferase activity was routinely normal-
ized by the amount of protein used in the assay. For Western blotting
analysis of these cell lysates, aliquots of cell lysate were resolved by
SDS^PAGE and transferred onto nitrocellulose membranes. Western
blotting with anti-ABIN-2 antibodies on these membranes was per-
formed according to standard procedure [19].
2.4. Immuno£uorescence microscopy
Transfected 293T cells were seeded onto glass coverslips coated with
poly-L-lysine. Slides were placed in DMEM containing 10% fetal calf
serum, and cells were allowed to grow overnight until they reached a
semi-con£uent state. The cultured cells were washed and ¢xed with
3% formaldehyde in phosphate-bu¡ered saline (PBS). Fixed cells were
¢rst incubated with anti-ABIN-2 antibodies, washed twice in PBS,
and reacted with £uorescein-conjugated secondary antibodies. Cells
were washed again with PBS, analyzed under a £uorescence micro-
scope, and photographed.
3. Results and discussion
3.1. ABIN-2 exerts transactivation activity in yeast
ABIN-2 was previously identi¢ed as one of the LKB1-in-
teracting proteins by yeast two-hybrid screening in our labo-
ratory [14]. While we were in the process of recon¢rming the
protein^protein interaction between ABIN-2 and LKB1 in the
yeast two-hybrid assay, we discovered that ABIN-2 fused to
the DNA BD of Gal4p could drive the expression of reporter
gene, LacZ, without the presence of the Gal4pAD. On the
other hand, the fusion of ABIN-2 with the Gal4pAD did
not cause the expression of LacZ, suggesting that the trans-
activation by ABIN-2 required a speci¢c DNA-binding activ-
ity toward the target gene.
There are four potential coiled-coil domains predicted in
the sequence of ABIN-2 [14]. Sequential deletion of these
coiled-coil domains from its N-terminus was generated and
tested for the transactivation activity in yeast. The result
shown in Fig. 1 indicated that the transcriptional activation
of ABIN-2 was mainly located in the C-terminal half of the
protein, from amino acids 196 to 429. From the analysis of
these overlapping constructs, two regions in the sequence of
ABIN-2, amino acids 196^253 and 346^429, appeared to be
essential for transactivating activity (Fig. 1). In addition, the
observed transcriptional activation by ABIN-2 was not lim-
ited to the fusion of Gal4pBD. When the proper DNA BD
was provided, ABIN-2 exerted its transcriptional activation.
This was demonstrated by fusing ABIN-2 to the bacterial
DNA-binding protein LexA; ABIN-2 was able to cause the
expression of reporter gene under the regulation of LexA
operator sequence as well (data not shown). Judged by its
lack of DNA-binding activity, as shown above, and no pre-
dicted sequence or structural features which resemble known
transcription factor, ABIN-2 is probably not a transcription
factor by itself but may be a novel transcriptional coactivator.
3.2. Regulation of ABIN-2 transactivation in mammalian cells
To test whether ABIN-2 could behave as a transcriptional
coactivator in mammalian cells, we performed a similar trans-
activation assay in the mammalian expression system using
luciferase as a reporter gene under Gal4-responsive regulation.
A mammalian expression construct of Gal4BD^ABIN-2 was
transfected into 293T cells together with the reporter gene
construct. The successful expression of the Gal4BD^ABIN-2
fusion protein in 293T cells was ¢rst con¢rmed by Western
analysis (Fig. 2A). To our surprise, unlike in the case of yeast
expression, the full-length ABIN-2 fused with Gal4BD was
not able to drive the expression of reporter gene after trans-
fection (Fig. 2B). We then asked the reason why the full-
length ABIN-2 failed to activate in the mammalian cells. Since
Gal4BD-fused
      ABIN-2
1      24       62             122                196            253                     346                  429 
Full length
62-429
123-429
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253-429
1-346
Transactivation
+
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_
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Fig. 1. Transactivation assay of ABIN-2 in yeast. Various lengths of truncated ABIN-2 as indicated by the amino acid numbers were fused to
Gal4pBD and transformed into yeast. The transactivation was measured by the expression of the reporter gene, LacZ. A positive sign indicated
the expression of active L-galactosidase analyzed both by colony-¢lter lift and liquid assays. The hatched boxes shown on the sequence of
ABIN-2 are the potential coiled-coil regions. The boxes shown at the bottom are two domains of ABIN-2 important for transactivation.
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our previous work has demonstrated that the full-length
ABIN-2 was localized exclusively in the cytoplasm when ex-
pressed in 293T cells [14], we suspected that the Gal4BD^
ABIN-2 protein might not be present in the nucleus and,
thus, failed to activate transcription. When examined by in-
direct £uorescent microscopy, it was found that the expressed
Gal4BD^ABIN-2 was localized in the cytoplasm (Fig. 3A).
This result was unexpected, as the yeast Gal4BD, which con-
tains a conserved nuclear localization signal, would drive its
fusion protein into the nucleus and has been successfully used
in the transactivation analysis in several mammalian systems
[20^22]. It appeared that other factors might be involved in
preventing Gal4BD^ABIN-2 from entry into the nucleus and
hence failed to activate transcription.
Since the ¢rst 195 amino acids of ABIN-2 were shown to be
dispensable for the transactivation in yeast (Fig. 1), we then
examined the transactivation activity of Gal4BD^ABIN-
2196429, in which its N-terminal 195 amino acid were deleted,
in 293T cells. Surprisingly, the truncated Gal4BD^ABIN-
2196429 protein readily stimulated the reporter gene expres-
sion to a great extent (Fig. 2B). From indirect £uorescent
microscopic examination, most Gal4BD^ABIN-2196429 was
shown to localize in the nucleus (Fig. 3G). It seems that the
transactivation of ABIN-2 in mammalian cells was dependent
on its subcellular localization, and the N-terminal portion of
ABIN-2 likely played a role in regulating its localization. The
truncation of 62 or 123 amino acids from the N-terminus of
ABIN-2 was not su⁄cient to allow the Gal4BD-fused proteins
to enter the nucleus, suggesting that the region responsible for
ABIN-2 localization is between amino acids 123 and 196 (Fig.
3C,E). Furthermore, the e⁄ciency of nuclear localization of
the fusion protein Gal4BD^ABIN-2196429 was relatively
high: about 80% was found in the nucleus (Fig. 3G), com-
pared to about 50% of the protein localized in the nucleus
when ABIN-2196429 was expressed without Gal4BD fragment
[14]. This study supported that the nuclear localization poten-
tial by the Gal4BD-fused protein was functional in 293T cells,
but was subjected to the in£uence of the N-terminal half of
ABIN-2.
It is possible that the N-terminal 195 amino acids of ABIN-
2 could bind to a protein in the cytoplasm, thereby preventing
the entry of Gal4BD^ABIN-2 into the nucleus. We have
searched for such proteins that associate with the N-terminus
of ABIN-2 and are responsible for the retention of ABIN-2 in
the cytoplasm by yeast two-hybrid screening. Our preliminary
result has discovered that ¢lamin (actin-binding protein-280),
which is a cytoplasmic protein, has strong interaction with
ABIN-21196 (our unpublished results). The signi¢cance of
the interaction awaits further characterization.
Several distinct mechanisms have been identi¢ed for the
post-translational activation of transcription factors in re-
sponse to multiple cellular stimuli [23]. One particular mode
of activation is proteolytic cleavage of these factors that al-
lows them to enter the nucleus [23]. We speculate that a pro-
teolytic mechanism could also be involved in generating a
nucleus-bound and active ABIN-2 molecule. This cleavage
may be executed under certain physiological circumstances.
Whether the truncated form of ABIN-2 is present endoge-
nously is still unclear at present. Alternatively, the full-length
ABIN-2 may still have the transactivating activity in mamma-
lian cells without any cleavage event. This is consistent with
the ¢nding that the full-length ABIN-2 transactivates in yeast.
To accomplish the transactivation, ABIN-2 could access the
genome during the mitotic process when the nuclear envelope
breaks down. The notion that ABIN-2 plays a role in regulat-
ing gene expression during mitosis is tempting. Several reports
have shown that there is unusual gene activation during the
process of mitosis in various organisms [24^26]. In one partic-
ular case, the recruitment of a chromatin-remodeling complex
was involved in the expression of certain genes that were
essential for mitotic exit [27]. This correlates with the ¢nding
that ABIN-2 has the ability to interact with the component of
the chromatin-remodeling complex as described below. Fi-
nally, we cannot rule out the possibility that other speci¢c
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Fig. 2. Transactivation of ABIN-2 in mammalian cells. A: Western
analysis of the expressed ABIN-2s in mammalian cells by anti-
ABIN-2 serum. Each of the truncated ABIN-2s was fused to
Gal4pBD as indicated and transfected into 293T cells. The protein
molecular weight markers are shown on the left. B: The transactiva-
tion activity of ABIN-2 in mammalian cells. The activity is shown
by the relative activity of luciferase measured from each cell lysate
against the basal activity from cells without transfection. All assays
were performed in triplicate and repeated twice.
Table 1
Loss of the transactivation activity of ABIN-2 in PCY2*
Gal4BD^ Gal4AD^ Yeast L-galactosidase
(nmol/min per mg protein)
LKB1 ABIN-2 PCY2 800S 35
ABIN-2 ^ PCY2 250S 22
LKB1 ABIN-2 PCY2* 780S 40
ABIN-2 ^ PCY2* 10S 3
The measurement of L-galactosidase activity was performed by liq-
uid assay [16]. Data shown represent mean values of the speci¢c ac-
tivity of L-galactosidase per mg of protein SS.E.M. of triplicate
tubes from two independent experiments.
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factors might be required to transport ABIN-2 into the nu-
cleus more e⁄ciently.
That the full-length ABIN-2 fused to Gal4BD had a signi¢-
cant transactivation activity in yeast was somewhat puzzling
(Table 1; second row). When the subcellular localization of
Gal4BD^ABIN-2 was examined in yeast, the expressed pro-
tein was distributed exclusively in the nucleus as expected
(data not shown). We speculate that the yeast cell could
lack a similar ABIN-2-interacting protein to retain ABIN-2
in the cytoplasm. Or, given the fact that Gal4p is a genuine
yeast transcription factor, Gal4BD could possess a distinct
nuclear localization mechanism in yeast as opposed to that
of mammalian cells.
3.3. ABIN-2 interacts with a component of the
chromatin-remodeling complex
In order to further characterize the function of ABIN-2, we
were interested in searching for other cellular factors which
are associating with ABIN-2 and, thus, would provide infor-
mation on how ABIN-2 could participate in transcriptional
regulation. Since ABIN-2 alone fused to Gal4BD possesses
transactivating activity in yeast, it cannot be used directly as
bait in the standard two-hybrid screening system. Therefore,
we adopted a genetic approach by ¢rst chemically mutageniz-
ing the yeast strain, PCY2, with EMS in order to ¢nd a mu-
tant strain which would allow us to screen for the ABIN-2-
interacting proteins. This strategy was based on the assump-
tion that the mediators for the transactivation by ABIN-2 and
for the Gal4p-activated transcription in the two-hybrid reac-
tion were di¡erent. Thus, mutational inactivation of one of
the mediators exclusively involved in the ABIN-2 transactiva-
tion may not interfere with the activity of Gal4p required for
a standard yeast two-hybrid analysis.
After screening 20 000 EMS-mutagenized colonies of PCY2,
we obtained a mutant strain, designated as PCY2*, that
showed a speci¢c defect for the ABIN-2 transactivation (Ta-
ble 1). In the PCY2* strain, unlike in PCY2, Gal4BD-fused
ABIN-2 alone no longer showed any transactivation activity.
However, the interaction between Gal4BD^LKB1 and Gal4-
AD^ABIN-2 in PCY2* occurred normally in the two-hybrid
analysis. This suggested that the transcriptional activity by the
complex between Gal4BD and Gal4AD through the interac-
tion of Gal4BD^LKB1 and Gal4AD^ABIN-2 was still func-
tional in this mutant. Thus, PCY2* was chosen as the host
strain for the subsequent two-hybrid screening work. The mo-
lecular basis of the PCY2* mutation remains to be determined
in the future.
To search for ABIN-2-interacting proteins, we chose to use
the ABIN-2196429 DNA fragment as bait in our two-hybrid
screening to avoid getting redundant clones, which were asso-
ciated with ABIN-21196, collected in our previous screening.
After screening of 55 000 colonies, a positive clone was ob-
tained and subjected to further analysis. The recovered plas-
mid was later found to contain a complete cDNA insert,
which was sequenced and shown to be identical to the human
BAF60a gene. BAF60a is a component of the SWI^SNF
chromatin-remodeling complex that has been shown to acti-
vate transcription by remodeling nucleosomes to permit access
of transcription factors and plays important roles in gene ex-
pression throughout eukaryotes [28,29]. Thus, it is likely that
ABIN-2 could exert its transcriptional activation by recruiting
a chromatin-remodeling complex to the site of the target gene
through the interaction with BAF60a. Using a deletion anal-
ysis of ABIN-2 in yeast, we further mapped the BAF60a-in-
teracting region of ABIN-2 within the stretch of amino acids
ranging from 196 to 253 (Fig. 4A). The fact that ABIN-21346
bound BAF60a but failed to transactivate the reporter gene
demonstrated that another domain, from amino acids 346 to
429, is required for transactivating activity (Fig. 1). It is likely
this second domain could also mediate the binding with other
factors, in addition to BAF60a, essential for transactivation.
The region of BAF60a responsible for interacting with ABIN-
2 was also mapped at two areas, ranging from amino acids 1
to 175 and 305 to 380 (Fig. 4B).
The ¢nding that ABIN-2 has transactivating activity and
associates with a component of chromatin-remodeling com-
6
Fig. 3. Subcellular localization of various ABIN-2 constructs expressed in 293T cells by transient transfection. The ectopically expressed
Gal4BD-fused ABIN-2 constructs were detected by indirect immuno£uorescent microscopy. Detection of expressed proteins was performed us-
ing mouse polyclonal antisera against ABIN-2, followed by immuno£uorescent staining with Rhodamin-conjugated secondary antiserum to ex-
amine the localization of ABIN-2fulllength (A), ABIN-262429 (C), ABIN-2123429 (E), ABIN-2196429 (G) and ABIN-21346 (I), respectively. Cells
were also stained with Hoechst to show the location of nuclei (B,D,F,H,J). Arrows indicate the corresponding cells shown on the left panel
with positive immunostaining.
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Fig. 4. Mapping the interacted regions between ABIN-2 and
BAF60a in yeast. A: Domain mapping of ABIN-2 interacting with
BAF60a. B: Domain mapping of BAF60a interacting with ABIN-2.
Both interactions were performed by the standard yeast two-hybrid
method. Boxes shown at the bottom of each panel are the regions
mapped to be essential for the interaction in each analysis.
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plexes, BAF60a, is particularly intriguing. BAF60a has been
illustrated as a determinant of the transactivation potential of
the transcription factor c-Fos/c-Jun dimers in mouse [30]. De-
letion analysis of the mouse BAF60a revealed the location of
two regions spanning amino acids 1^175 and 307^366, which
is responsible for binding with either c-Fos or c-Jun [30]. Here
we demonstrate that the human BAF60a, which shares high
homology with the mouse counterpart, is an interacting pro-
tein of ABIN-2. More importantly, the protein domains of the
human BAF60a responsible for binding to ABIN-2 over-
lapped precisely with the areas that bind to c-Fos/c-Jun in
mouse (Fig. 4B). These areas of BAF60a should potentially
represent important domains in association with cellular acti-
vators leading to transcriptional activation.
In the ¢eld of gene regulation, transcriptional coactivator
complexes that facilitate the action of sequence-speci¢c gene
activators have emerged over the last decade [31,32]. Many of
these factors are pivotal to our current understanding of
mechanisms in cell growth, di¡erentiation, development, and
tumor formation [31,32]. We report here that ABIN-2 is likely
to represent such a novel transcriptional coactivator.
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